GlassScriptPhysician profile
Matthew C Munda
NPI 1114300316
$8,236.49
in general payments reported to CMS, 2019-2025
42 companies · $981 in 2025
The $981 reported for 2025 was more than what 86% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,111 · 2022: $1,606 · 2023: $1,856 · 2024: $1,683 · 2025: $981.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,519.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,519.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,316.32 | 2021-2025 | Relistor |
| Collegium Pharmaceutical, INC. | $755.41 | 2021-2025 | Belbuca, Xtampza |
| Forte Bio-Pharma LLC | $742.58 | 2022-2025 | Prolate, Nalocet, Tanlor |
| Lundbeck LLC | $581.70 | 2021-2025 | Vyepti |
| Abbvie INC. | $477.74 | 2021-2025 | |
| Teva Pharmaceuticals USA, INC. | $408.82 | 2021-2025 | Ajovy |
| Pfizer INC. | $297.46 | 2023-2025 | |
| Medtronic, INC. | $261.53 | 2022-2025 | Intellis Adaptivestim, Inceptiv |
| Merck Sharp & Dohme LLC | $231.55 | 2021-2023 | Belsomra |
| Amgen INC. | $221.73 | 2021-2022 | |
| Scilex Pharmaceuticals INC. | $215.03 | 2021-2024 | Ztlido |
| Antares Pharma, INC. | $203.65 | 2021-2025 | Xyosted, Tlando, Nocdurna |
| Lilly USA, LLC | $195.26 | 2021-2023 | Emgality, Reyvow |
| Orexo US, INC. | $193.60 | 2021-2023 | Zubsolv |
| Nalu Medical, INC. | $188.68 | 2024-2025 | Nalu Neurostimulation System |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Munda listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.